Counter screen for luciferase inhibitors of Dense Granule Secretion. 20ul of 1.5uM ATP (Sigma, #A1852)  in PBS is plated in 384-well white assay plates (Aurora, 00030721) and was exposed to the 1584 cherry-picked compounds chosen based on activity of the platelet dense granule release primary screen (AID1663) and structure to compounds with the highest activity, to provide some SAR data.  A dose-response plate with the positive control Resveratrol (Sigma #5010, Lot#038K5202, BRD-K80738081, CID445154) was included in the run  After compound addition, the detection reagent CellTiter-Glo (Promega, G755) was resuspend and diluted in PBS by the same protocol as for the primary screen.  Luminescence measurements are taken immediately after reagent addition. Expected Outcome: Compounds that inhibit luciferase from acting on the luciferin substrate contained within the CellTiter-Glo reagent will exhibit a decrease in luminescent signal. Normalization and dose-response curves will be fit using the Genedata Screener applications.  The activity determination from this assay (IC50) will be compared to the activity determined from retest of the primary screen by calculation of the ratio of the two.  The compounds showing a greater than 10-fold difference in activity will be further analyzed for the specific mechanism in which platelet activation is inhibited. Taken from 2016-02-W01-01 1.  Reagents are prepared for the assay:      a. Frozen aliquots of 10mM ATP in PBS is thawed and diluted to 1.5uM in PBS.  Enough reagent is prepared for the run (8ml/plate + extra dead volume for liquid handling).      b.  Frozen aliquots of CellTiter-Glo (Promega) (CTG) in PBS is thawed and diluted in PBS 1:4. Enough reagent is prepared for the run (4ml/plate + extra dead volume for liquid handling). 2.  A MultiDrop Combi (Thermo) is prepared with a standard cassette that is washed and primed with the reagent.  Plates are filled with 20&#956;l of 1.5uM ATP in PBS. 3. Compounds are added using the CyBi-Well (CyBio Inc.).  50nl are pinned using the 25nl pin array, which is programed for 2 seperate dips into the compound plate, seperated by a pin wash cycle. 4. During compound addition, a MultiDrop Combi is prepared for second reagent addition by washing cassette and priming with new reagent. 5.  Upon completion of compound addition, 10&#956;l of CTG (1:4) in PBS is added to every well. 6.  Plates are transferend to an Envison Plate Reader (Perkin Elmer) to measure luminesence.  The ultra sensitive detection is used, with the 1536 aperture in place, to decrease bleed-through from adjacent wells.  Read time is 0.1s/well.
bao:BAO_0001077 "1663" ; # "is alternate confirmatory assay of" -> "1663"
bao:BAO_0000812 "1678" ; # "has summary assay" -> "1678"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0000595 bao:BAO_0000467 ; # "has alternate assay format" -> "alternate assay format"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000291 ; # "has participant" -> "oxidoreductase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002735 ; # "is bioassay type of" -> "luciferase enzyme activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
bao:BAO_0000207 bao:BAO_0000045 ; # "has detection method" -> "luminescence method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of inhibitors of platelet activation and dense granule release" ; # "screening campaign name" -> "Identification of inhibitors of platelet activation and dense granule release"
bao:BAO_0002853 "Luminescence Biochemical Dose Response HTS to Identify Inhibitors of Luciferase" ; # "has assay title" -> "Luminescence Biochemical Dose Response HTS to Identify Inhibitors of Luciferase"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000515 ; # "has assay footprint" -> "384 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BA0_0090012 "Resveratrol" ; # "has participant" -> "Resveratrol"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
bao:BAO_0000740 "median of negative control wells" ; # "has assay control" -> "median of negative control wells"
bao:BAO_0000740 bao:BAO_0000334 ; # "has assay control" -> "background control"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000776 ; # "has participant" -> "Adenosine triphosphate" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_25078> ; # "has role" -> "luciferin" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 bao:BAO_0000141 ; # "has participant" -> "Luciferin 4-monooxygenase"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_41716> ; # "has organism" -> "Photuris pennsylvanica"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q27757" ; # "uniprot ID" -> "Q27757"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "41716" ; # "NCBI taxonomy ID" -> "41716"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000682 ; # "has assay kit" -> "CellTiter-Glo Luminescent Cell Viability Assay"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000303 ; # "has manufacturer" -> "Promega" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
bao:BAO_0002787 "8" ; # "has concentration-point number" -> "8"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Uma" ; # "Annotated by" -> "Uma"
